Cryolife (CRY) Scheduled to Post Earnings on Tuesday

Cryolife (NYSE:CRY) is set to issue its quarterly earnings data after the market closes on Tuesday, February 13th. Analysts expect the company to announce earnings of $0.11 per share for the quarter.

Shares of Cryolife (CRY) opened at $17.65 on Tuesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 4.90 and a current ratio of 5.96. Cryolife has a 52-week low of $14.02 and a 52-week high of $24.00. The company has a market cap of $610.60, a PE ratio of 63.04 and a beta of 0.77.

CRY has been the topic of several analyst reports. Canaccord Genuity reissued a “buy” rating and set a $25.00 price target on shares of Cryolife in a research report on Monday, October 9th. Lake Street Capital boosted their price target on shares of Cryolife to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research cut shares of Cryolife from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. TheStreet cut shares of Cryolife from a “b” rating to a “c+” rating in a research report on Monday, October 30th. Finally, Northland Securities reissued a “buy” rating and set a $23.50 price target on shares of Cryolife in a research report on Monday, November 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Cryolife currently has an average rating of “Buy” and an average target price of $23.63.

In other news, CAO Amy Horton sold 4,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total value of $76,000.00. Following the sale, the chief accounting officer now directly owns 98,705 shares of the company’s stock, valued at approximately $1,875,395. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO David Ashley Lee sold 33,190 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total transaction of $630,610.00. Following the completion of the sale, the chief financial officer now directly owns 324,339 shares in the company, valued at $6,162,441. The disclosure for this sale can be found here. Insiders have sold a total of 58,190 shares of company stock worth $1,119,210 over the last three months. Insiders own 6.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Cryolife (CRY) Scheduled to Post Earnings on Tuesday” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/06/cryolife-cry-scheduled-to-post-earnings-on-tuesday.html.

About Cryolife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Earnings History for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply